Hamid Moradi

Title: Hamid Moradi: Innovator in RNAi Therapeutics

Introduction

Hamid Moradi is a prominent inventor based in Laguna Hills, California. He has made significant contributions to the field of RNA interference (RNAi) therapeutics, particularly in the development of agents that inhibit the expression of complement component C3.

Latest Patents

Moradi holds a patent for "RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use." This patent describes RNAi agents, such as double-stranded RNAi agents or siRNAs, that effectively inhibit the gene expression of Complement Component C3. The patent also details pharmaceutical compositions that incorporate these RNAi agents and outlines methods for their use. The C3 RNAi agents can be conjugated to targeting ligands, including those comprising N-acetyl-galactosamine, to enhance delivery to hepatocyte cells. The in vivo delivery of these agents facilitates the inhibition of C3 gene expression, which can be beneficial in treating diseases and disorders associated with C3 gene expression, including IgA nephropathy, C3 glomerulopathy, and paroxysmal nocturnal hemoglobinuria.

Career Highlights

Moradi is currently associated with Arrowhead Pharmaceuticals, Inc., where he continues to advance his research in RNAi technologies. His work has the potential to impact various complement-mediated renal diseases significantly.

Collaborations

Throughout his career, Moradi has collaborated with notable colleagues, including Jeffrey Carlson and Yichen Wang, contributing to the advancement of innovative therapeutic solutions.

Conclusion

Hamid Moradi's work in RNAi therapeutics exemplifies the innovative spirit of modern science. His contributions are paving the way for new treatments for complex diseases, showcasing the importance of research and development in the pharmaceutical industry.